Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
The oral tablet may be more suitable for those who are uncomfortable with injections
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors not yet approved by the MHRA or EMA for clinical use in the UK
Similarly, a 2023 study published in the Journal of the American Medical Association (JAMA) found that individuals taking GLP-1 drugs were more than four times as likely to experience bowel obstruction compared with patients using bupropion-naltrexone, another class of weight-management medication
Increase fruits, vegetables and other fibre-enriched foods in your diet
US$ 22.35
US$ 27.33
US$ 26.74
US$ 23.32
US$ 23.67
